We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Microbial Community Composition and Metabolism in Cystic Fibrosis

This study is currently recruiting participants.
Verified July 2017 by Thomas Martin, Boston Children's Hospital
Sponsor:
ClinicalTrials.gov Identifier:
NCT00954018
First Posted: August 6, 2009
Last Update Posted: August 2, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
Massachusetts Institute of Technology
Harvard Medical School
Information provided by (Responsible Party):
Thomas Martin, Boston Children's Hospital
August 5, 2009
August 6, 2009
August 2, 2017
August 2009
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00954018 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Microbial Community Composition and Metabolism in Cystic Fibrosis
Respiratory Microbial Community Composition and Metabolism in Cystic Fibrosis
Scientist have begun to realize that many types of bacteria often live together as a complex community, and the investigators wish to apply that idea to the bacteria in the respiratory system of people with Cystic Fibrosis (CF). It is possible that the survival of the many millions of bacteria in the CF lung depends on the production of special chemicals that might be made only by very few types of bacteria. If that is true, medicines that interfere with those chemicals could treat the lung infections that cause trouble for nearly all people with CF. The investigators wish to study the production of several potentially critical chemicals by the respiratory bacteria and to examine the effect of those chemicals on the makeup of the entire community of bacteria. To detect all the bacteria in that community, the investigators will use new methods that use bacterial genetic information and can detect hundreds of different types of bacteria in respiratory samples of individual CF patients.
Not Provided
Observational
Observational Model: Other
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
throat swabs or sputum
Non-Probability Sample
Cystic fibrosis patients will be contacted during clinical care visits and inpatient hospitalizations.
Cystic Fibrosis
Not Provided
  • Cystic Fibrosis patient during outpatient clinic visit
  • Cystic Fibrosis patients during hospitalization
  • CF patients about to have sinus surgery and bronchoscopy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
120
Not Provided
Not Provided

Inclusion Criteria:

  • confirmed diagnosis of Cystic Fibrosis
  • 2 to 55 years of age

Exclusion Criteria:

Sexes Eligible for Study: All
2 Years to 55 Years   (Child, Adult)
No
United States
 
 
NCT00954018
09-04-018
No
Not Provided
Not Provided
Thomas Martin, Boston Children's Hospital
Boston Children’s Hospital
  • Massachusetts Institute of Technology
  • Harvard Medical School
Not Provided
Boston Children’s Hospital
July 2017